Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq ® ) in adults with severe haemophilia A: efficacy and safety-Reference-Cited by-同舟云学术

Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq ® ) in adults with severe haemophilia A: efficacy and safety

Published:2015-08-28 Issue:2 Volume:22 Page:225-231
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Lissitchkov T.¹,Hampton K.²,Depka M.³,Hay C.⁴,Rangarajan S.⁵,Tuddenham E.⁶,Holstein K.⁷,Huth‐Kühne A.⁸,Pabinger I.⁹,Knaub S.¹⁰,Bichler J.¹⁰,Oldenburg J.¹¹

Affiliation:

1. Specialised Hospital for Active Treatment “Joan Pavel” Sofia Bulgaria

2. Royal Hallamshire Hospital Sheffield UK

3. Werlhof‐Institut für Hämostaseologie GmbH Hannover Germany

4. Manchester Royal Infirmary Manchester UK

5. Basingstoke and North Hampshire Hospital BasingstokeUK

6. Royal Free Hospital London UK

7. University Hospital Hamburg‐Eppendorf HamburgGermany

8. SRH Kurpfalzkrankenhaus and Hemophilia Center Heidelberg Germany

9. Medical University of Vienna Vienna Austria

10. Octapharma AG Lachen Switzerland

11. Institute of Experimental Haematology and Transfusion Medicine Bonn Germany

Funder

Pfizer

Baxter International

Bayer

Biogen Idec

CSL Behring

Novo Nordisk

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12793

Reference40 articles.

1. The modern treatment of haemophilia: a narrative review;Franchini M;Blood Transfus,2013

2. Treatment of hemophilia: a review of current advances and ongoing issues

3. Prophylaxis in haemophilia should be life‐long;Makris M;Blood Transfus,2012

4. Guidelines for the management of hemophilia

5. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simoctocog alfa (Nuwiq^®) in children: early steps in life’s journey for people with severe hemophilia A;Therapeutic Advances in Hematology;2024-01

2. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

3. Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method;European Journal of Haematology;2023-08-16

4. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A—Final efficacy and safety results from the NuProtect study;European Journal of Haematology;2023-07-13

5. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial;The Lancet Haematology;2023-05